Literature DB >> 33922425

Cannabis Use among Older Persons with Arthritis, Cancer and Multiple Sclerosis: Are We Comparing Apples and Oranges?

Brian Kaskie1, Hyojung Kang2, Divya Bhagianadh1, Julie Bobitt3.   

Abstract

Although researchers have identified medications that relieve symptoms of multiple sclerosis (MS), none are entirely effective and some persons with multiple sclerosis (PwMS) use alternatives. Our study compared cannabis use among PwMS (N = 135) and persons diagnosed with arthritis (N = 582) or cancer (N = 622) who were age 60 and older, enrolled in the State of Illinois Medical Cannabis Program, and invited to complete a survey fielded between June and September, 2019. We used logistic regression to identify significant differences in self-reported effects of cannabis on psychological wellbeing, quality of life, and three behavioral outcomes, and we also considered effects of past year opioid use relative to these outcomes. We found that the majority of individuals from all groups used cannabis to address pain and improve quality of sleep. While PwMS reported lower baseline levels across all five outcomes, we found that the reported effects of cannabis were largely comparable across the groups. We also found that cannabis benefitted persons with sleep and digestive issues regardless of condition, whereas persons who used opioids in addition to cannabis were less likely to experience an improvement in any of the outcomes. This comparative evaluation suggests that cannabis' effects are not specific to MS, arthritis, or cancer as much as they impact processes common among these distinct conditions. We also found evidence that cannabis may be a viable alternative to opioids for those with these conditions and experiencing pain.

Entities:  

Keywords:  cannabis; multiple sclerosis; older adults; opioids

Year:  2021        PMID: 33922425     DOI: 10.3390/brainsci11050532

Source DB:  PubMed          Journal:  Brain Sci        ISSN: 2076-3425


  20 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients.

Authors:  Philippe Lucas; Zach Walsh
Journal:  Int J Drug Policy       Date:  2017-02-09

3.  Cannabis use in Spanish patients with multiple sclerosis: fulfilment of patients' expectations?

Authors:  Jose E Martínez-Rodríguez; Elvira Munteis; Mar Carreño; Yolanda Blanco; Jaume Roquer; Sergio Abanades; Francesc Graus; Albert Saiz
Journal:  J Neurol Sci       Date:  2008-08-08       Impact factor: 3.181

4.  Rates of cannabis use in patients with cancer.

Authors:  K Martell; A Fairchild; B LeGerrier; R Sinha; S Baker; H Liu; A Ghose; I A Olivotto; M Kerba
Journal:  Curr Oncol       Date:  2018-06-28       Impact factor: 3.677

5.  Assessing Health-Related Outcomes of Medical Cannabis Use among Older Persons: Findings from Colorado and Illinois.

Authors:  James Alton Croker; Julie L Bobitt; Kanika Arora; Brian Kaskie
Journal:  Clin Gerontol       Date:  2020-08-26       Impact factor: 2.619

6.  Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants.

Authors:  Stacey S Cofield; Amber Salter; Tuula Tyry; Christina Crowe; Gary R Cutter; Robert J Fox; Ruth Ann Marrie
Journal:  Neurol Clin Pract       Date:  2017-08

7.  The prevalence of MS in the United States: A population-based estimate using health claims data.

Authors:  Mitchell T Wallin; William J Culpepper; Jonathan D Campbell; Lorene M Nelson; Annette Langer-Gould; Ruth Ann Marrie; Gary R Cutter; Wendy E Kaye; Laurie Wagner; Helen Tremlett; Stephen L Buka; Piyameth Dilokthornsakul; Barbara Topol; Lie H Chen; Nicholas G LaRocca
Journal:  Neurology       Date:  2019-02-15       Impact factor: 9.910

Review 8.  Review of Two Popular Eating Plans within the Multiple Sclerosis Community: Low Saturated Fat and Modified Paleolithic.

Authors:  Terry L Wahls; Catherine A Chenard; Linda G Snetselaar
Journal:  Nutrients       Date:  2019-02-07       Impact factor: 5.717

Review 9.  Opportunities for cannabis in supportive care in cancer.

Authors:  Amber S Kleckner; Ian R Kleckner; Charles S Kamen; Mohamedtaki A Tejani; Michelle C Janelsins; Gary R Morrow; Luke J Peppone
Journal:  Ther Adv Med Oncol       Date:  2019-08-01       Impact factor: 8.168

10.  Defining the clinical course of multiple sclerosis: the 2013 revisions.

Authors:  Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman
Journal:  Neurology       Date:  2014-05-28       Impact factor: 9.910

View more
  1 in total

1.  Adherence, Safety, and Effectiveness of Medical Cannabis and Epidemiological Characteristics of the Patient Population: A Prospective Study.

Authors:  Lihi Bar-Lev Schleider; Raphael Mechoulam; Inbal Sikorin; Timna Naftali; Victor Novack
Journal:  Front Med (Lausanne)       Date:  2022-02-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.